Washington D.C. [USA], Oct. 27 : Each year, more than 4,000 children and teens are diagnosed with brain cancer and the disease kills more children than any other cancer.

Researchers of Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified an existing group of drugs that appear to reduce or eliminate a certain subgroup of childhood brain cancers while sparing normal brain tissue.

The research was conducted using a new zebrafish animal model system developed by the researchers, which closely resembles an aggressive subtype of pediatric brain tumours.

"For many pediatric brain tumors no cell or animal model exist to test targeted, or personalized, medications that could significantly improve survival and alleviate the harmful side effects of conventional therapies," explained researcher Rodney Stewart. "Indeed, children with rare brain tumors have few options for life-saving treatment. Our hope is by creating this animal model we will be a step closer to finding effective therapies."

The researchers studied a particularly aggressive pediatric brain tumor, known as primitive neuroectodermal tumors of the central nervous system (CNS-PNET) for which few animal or cell line models exist.

Without an animal model or cell lines, Stewart explained, treatments could not be tested. Over the course of seven years, Stewart and his team worked to develop a model which, at the genomic level, closely modeled the human condition they hoped to study.

"We spent a lot of time comparing brain tumors arising in fish with related human brain cancers at the molecular genetic level," Stewart said. "This is important because these childhood brain cancers are rare and as a result, there are few patient samples to study for comparisons."

Human tissue samples were necessary, however, in order to construct a reliable model. "We needed to reach out to several groups," he explained.

Stewart credits discoveries announced by two other groups studying similar cancers that opened the way for his group to move forward, "They were able to re-classify CNS-PNET tumors into distinct subgroups at the molecular level. That opened up a new avenue for our team because that stratification made it possible for us to really nail down what the zebrafish brain tumor model represents."

Using the model, Stewart's lab was able to test already existing compounds to see if they could find a targeted therapy that would work on one of the newly identified subgroups: the oligoneural or NB_FOXR2 CNS-PNET subgroup. Through work they had done to create the tumor model, they knew that a particular drug already in human clinical trials might work.

"When we treated the fish with MEK inhibitors -- drugs that inhibit an enzyme -- they exhibited a remarkable response," said Stewart. "Not only was the tumor burden reduced, it completely eliminated the tumor in about 80 percent of the fish and those tumors have not come back. This is a durable response from a transient treatment. It's what we look for in cancer therapy, an effective drug that can be taken for a certain amount of time but, after the cancer is gone, patients can stop taking the drug and go on living their lives."

Stewart is careful to emphasize that while the brain tumor type between fish and humans is similar, more studies are needed to determine if the results can be translated into the clinic. He would like to see his discovery in the hands of physicians as soon as possible.

"Currently, the outcome for children with these cancers is deplorable. We don't want to wait much longer," he said.

This study has been published in Cell Reports. (ANI)